2012
The immune reconstitution inflammatory syndrome after antiretroviral therapy initiation in patients with tuberculosis: findings from the SAPiT trial.
Naidoo K, Yende-Zuma N, Padayatchi N, Naidoo K, Jithoo N, Nair G, Bamber S, Gengiah S, El-Sadr WM, Friedland G, Abdool Karim S. The immune reconstitution inflammatory syndrome after antiretroviral therapy initiation in patients with tuberculosis: findings from the SAPiT trial. Annals Of Internal Medicine 2012, 157: 313-24. PMID: 22944873, PMCID: PMC3534856, DOI: 10.7326/0003-4819-157-5-201209040-00004.Peer-Reviewed Original ResearchMeSH KeywordsAdultAIDS-Related Opportunistic InfectionsAntibiotics, AntitubercularAnti-Retroviral AgentsCD4 Lymphocyte CountFemaleHIV InfectionsHumansImmune Reconstitution Inflammatory SyndromeImmunocompromised HostIncidenceKaplan-Meier EstimateMaleProspective StudiesRifampinRisk FactorsSeverity of Illness IndexTuberculosisConceptsImmune reconstitution inflammatory syndromeSequential treatment groupIncidence of IRISReconstitution inflammatory syndromeAntiretroviral therapy initiationART initiationTreatment groupsIRIS incidenceSAPiT trialInflammatory syndromeTherapy initiationTreatment initiationTuberculosis treatmentOpen-label clinical trialCells/LCo-infected patientsEarly ART initiationInitiation of ARTTuberculosis treatment initiationSmear-negative tuberculosisHigher hospitalization ratesWeeks of completionBaseline CD4Antituberculosis treatmentNonambulatory patients
2010
Infectious Disease Comorbidities Adversely Affecting Substance Users With HIV: Hepatitis C and Tuberculosis
Friedland G. Infectious Disease Comorbidities Adversely Affecting Substance Users With HIV: Hepatitis C and Tuberculosis. JAIDS Journal Of Acquired Immune Deficiency Syndromes 2010, 55: s37-s42. PMID: 21045598, PMCID: PMC4505738, DOI: 10.1097/qai.0b013e3181f9c0b6.Peer-Reviewed Original ResearchConceptsHepatitis CDrug interactionsDrug usersDrug useActive screening programsSpecial clinical challengeIsoniazid preventive therapySubstance abusersInjection drug usePharmacodynamic drug interactionsDrug-resistant organismsTreatment of tuberculosisInfectious disease comorbiditiesHIV/AIDSPreventive therapyTreatment initiationComorbid conditionsMedication adherenceHIV pandemicScreening programClinical challengeClinician expertiseTherapeutic successClinical consequencesInfection control